The emergence of compounds like copyright and Semaglutide signifies a remarkable shift in how we manage metabolic disorders. These new therapies belong to a class known as GLP-1 target agonists, which replicate the effects of a natural hormone that manages glucose levels and food intake. Originally, developed for diabetes, their effectiveness in… Read More